Eplerenone and IOP in Healthy Adults

Summary

The goal of this clinical trial is to determine whether eplerenone lowers eye pressure in healthy adults. Eplerenone is a medication approved by the U.S. Food and Drug Administration for other medical conditions. Researchers will compare eplerenone with placebo (a substance containing no active drug) to determine whether eplerenone affects intraocular pressure (IOP). Participants will receive both eplerenone and placebo during different study periods and will have their eye pressure measured throughout the study. Blood pressure, kidney function, and potassium levels will also be monitored for safety.

Conditions

• Intraocular Pressure (IOP)
• Healthy Adult

Interventions

DRUG

Eplerenone

Eplerenone 50 mg administered orally once daily for one week. In this randomized, double-masked crossover study, participants receive eplerenone during one treatment period and matching placebo during the other treatment period, with a two-week washout period between treatments.

DRUG

Microcrystalline Cellulose NF (placebo)

Matching placebo capsule containing Microcrystalline Cellulose NF, administered orally once daily for one week. The placebo is prepared by the Investigational Drug Service to match the study intervention for use in the double-masked crossover design.

Sponsors & Collaborators

• University of Florida

  lead OTHER

Principal Investigators

• Ramin Daneshvar, M.D. · University of Florida

Study Design

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

QUADRUPLE

Model

CROSSOVER

Eligibility

Min Age

18 Years

Max Age

50 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2026-10-01

Primary Completion

2027-02-01

Completion

2027-04-01

FDA Drug

Yes

Countries

• United States

Study Locations